Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial
Posted inClinical Updates news Oncology

Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial

A secondary analysis of the GAP70+ trial reveals that while 71.7% of older adults with advanced cancer prioritize quality of life, their clinical outcomes—including survival and toxicity—remain unchanged compared to those prioritizing survival, suggesting a systemic lack of responsiveness to patient goals.
Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma
Posted innews Oncology Otorhinolaryngology

Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma

A Phase 2 clinical trial of amivantamab, an EGFR-MET bispecific antibody, in recurrent or metastatic adenoid cystic carcinoma (ACC) showed a 72.2% clinical benefit rate. While the primary objective response rate was low, the high rate of disease stabilization highlights its potential in managing this rare malignancy.
Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial
Posted innews Oncology

Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial

The Phase 3 SACHI trial demonstrates that the combination of savolitinib and osimertinib significantly extends progression-free survival compared to chemotherapy in patients with MET-amplified, EGFR-mutated non-small-cell lung cancer who progressed on prior TKI therapy, offering a potent oral treatment alternative.
PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
Posted inGastroenterology news Oncology

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefining neoadjuvant standards for this aggressive malignancy.